Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors.

Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LA.

Clin Cancer Res. 2018 Jan 1;24(1):43-51. doi: 10.1158/1078-0432.CCR-17-1114. Epub 2017 Oct 13.

2.

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F.

Onco Targets Ther. 2016 Nov 30;9:7275-7283. eCollection 2016.

3.

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C.

J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23.

4.

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC.

Thyroid. 2014 Feb;24(2):232-40. doi: 10.1089/thy.2013.0078. Epub 2013 Sep 10.

PMID:
23721245
5.

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate.

Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD.

BMC Pharmacol Toxicol. 2013 Jan 14;14:7. doi: 10.1186/2050-6511-14-7.

6.

Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer.

Sosa JA, Balkissoon J, Lu SP, Langecker P, Elisei R, Jarzab B, Bal CS, Marur S, Gramza A, Ondrey F.

Surgery. 2012 Dec;152(6):1078-87. doi: 10.1016/j.surg.2012.08.036. Review.

PMID:
23158178
7.

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ.

Clin Cancer Res. 2012 Mar 1;18(5):1415-25. doi: 10.1158/1078-0432.CCR-11-2414. Epub 2012 Jan 10.

8.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P.

N Engl J Med. 2011 Jun 2;364(22):2119-27. doi: 10.1056/NEJMoa1012863.

9.

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJ.

Ann Oncol. 2011 Sep;22(9):2036-41. doi: 10.1093/annonc/mdq708. Epub 2011 Jan 27.

PMID:
21273348
10.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M.

Br J Cancer. 2010 Apr 27;102(9):1355-60. doi: 10.1038/sj.bjc.6605650. Epub 2010 Apr 13.

11.

Lymphatic mapping for staging of head and neck cancer.

Balkissoon J, Rasgon BM, Schweitzer L.

Semin Oncol. 2004 Jun;31(3):382-93. Review.

PMID:
15190496
12.

Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients.

Marincola FM, Balkissoon J, Schwartzentruber DJ, Hom SS, Concepcion R, Marcus SG, Yannelli J, Topalian SL, Parkinson DR, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1993 May 4;13(4):282-8.

PMID:
8334112
13.

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.

Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR.

Cancer Res. 1992 Dec 1;52(23):6561-6. Erratum in: Cancer Res 1993 Aug 15;53(16):3846. Cancer Res 1993 Dec 15;53(24):6079.

14.

Massive upper gastrointestinal bleeding in a patient with a duodenal diverticulum: a case report and review of the literature.

Balkissoon J, Balkissoon B, Leffall LD Jr, Posey DA Jr.

J Natl Med Assoc. 1992 Apr;84(4):365-7. Review.

15.

Vascular access in the cancer patient.

DeWitty RL Jr, Siram SM, Balkissoon J.

J Natl Med Assoc. 1986 Apr;78(4):289-91.

Supplemental Content

Loading ...
Support Center